With promising mid-stage trial results, berobenatide aims to make obesity treatment more convenient without compromising effectiveness.
The natural GLP-1 hormone survives in the body for only a few minutes before it is broken down. Drug developers overcome this limitation through advanced molecular engineering techniques.